Can AI speed a wave of custom medicines?

Biotech execs hope AI can help build 'n-of-1' drugs faster. Not yet, a new study suggests. 

May 14, 2024 Check out STAT+

Sponsored By

Courtesy Yiwei She STAT+ | Can AI build custom 'n-of-1' drugs faster? Maybe not yet, new case study suggests Advocates and biotech executives hope that AI can help speed a wave of custom medicines. A new study suggests that outcome may still be years away. By Jason Mast STAT+ | Element Biosciences, an Illumina rival, on its genomics ambitions — and why it hasn't gone public QA with Molly He: Element is betting its blend of accuracy and moderate price point can help it carve out a niche of academic and biopharma customers. By Jonathan Wosen Opinion: Making the promise of monoclonal antibody therapies available to all Life-saving monoclonal antibodies must be made accessible, affordable, and available to people with compromised immune systems. By Ken McEldowney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser